303 related articles for article (PubMed ID: 9607948)
21. Sustained release of flufenamic acid from a drug-triacetyl-beta-cyclodextrin complex.
Nakanishi K; Masukawa T; Nadai T; Yoshii K; Okada S; Miyajima K
Biol Pharm Bull; 1997 Jan; 20(1):66-70. PubMed ID: 9013809
[TBL] [Abstract][Full Text] [Related]
22. The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics.
Igami K; Ozawa M; Inoue S; Iohara D; Miyazaki T; Shinoda M; Anraku M; Hirayama F; Uekama K
J Pharm Pharmacol; 2016 May; 68(5):646-54. PubMed ID: 26255976
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy.
Lee Y; Kim IH; Kim J; Yoon JH; Shin YH; Jung Y; Kim YM
J Drug Target; 2011 Jun; 19(5):336-43. PubMed ID: 20615092
[TBL] [Abstract][Full Text] [Related]
24. Colon-specific delivery of dexamethasone from a glucoside prodrug in the guinea pig.
Tozer TN; Rigod J; McLeod AD; Gungon R; Hoag MK; Friend DR
Pharm Res; 1991 Apr; 8(4):445-54. PubMed ID: 1871038
[TBL] [Abstract][Full Text] [Related]
25. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative.
Ishiguro T; Morishita E; Iohara D; Hirayama F; Wada K; Motoyama K; Arima H; Uekama K
Int J Pharm; 2011 Oct; 419(1-2):161-9. PubMed ID: 21839823
[TBL] [Abstract][Full Text] [Related]
26. Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats.
Nagarsenker MS; Meshram RN; Ramprakash G
J Pharm Pharmacol; 2000 Aug; 52(8):949-56. PubMed ID: 11007065
[TBL] [Abstract][Full Text] [Related]
27. Release characteristics of endogenous constituents by exposure of small intestine to modified beta-cyclodextrins.
Tanino T; Ogiso T; Iwaki M; Yamaguchi T; Kakehi K
Biol Pharm Bull; 1999 Oct; 22(10):1099-105. PubMed ID: 10549863
[TBL] [Abstract][Full Text] [Related]
28. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
29. Hydrolysis behavior of prednisolone 21-hemisuccinate/beta-cyclodextrin amide conjugate: involvement of intramolecular catalysis of amide group in drug release.
Yano H; Hirayama F; Arima H; Uekama K
Chem Pharm Bull (Tokyo); 2000 Aug; 48(8):1125-8. PubMed ID: 10959575
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of indomethacin ester prodrugs: gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats.
Ogiso T; Iwaki M; Tanino T; Nagai T; Ueda Y; Muraoka O; Tanabe G
Biol Pharm Bull; 1996 Sep; 19(9):1178-83. PubMed ID: 8889037
[TBL] [Abstract][Full Text] [Related]
31. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
[TBL] [Abstract][Full Text] [Related]
32. Preparation of prednisolone-appended alpha-, beta- and gamma-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior.
Yano H; Hirayama F; Arima H; Uekama K
J Pharm Sci; 2001 Apr; 90(4):493-503. PubMed ID: 11170039
[TBL] [Abstract][Full Text] [Related]
33. Potential use of gamma-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin.
Abu Hashim II; Higashi T; Anno T; Motoyama K; Abd-ElGawad AE; El-Shabouri MH; Borg TM; Arima H
Int J Pharm; 2010 Jun; 392(1-2):83-91. PubMed ID: 20298768
[TBL] [Abstract][Full Text] [Related]
34. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid.
Yamaguchi T; Sasaki K; Kurosaki Y; Nakayama T; Kimura T
J Drug Target; 1994; 2(2):123-31. PubMed ID: 7915179
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid.
Jung YJ; Lee JS; Kim YM
J Pharm Sci; 2000 May; 89(5):594-602. PubMed ID: 10756325
[TBL] [Abstract][Full Text] [Related]
36. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
Ammar HO; Salama HA; Ghorab M; Mahmoud AA
Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of 4-biphenylacetic acid bioavailability in rats by its beta-cyclodextrin complex after oral administration.
Puglisi G; Santagati NA; Ventura CA; Pignatello R; Panico AM; Spampinato S
J Pharm Pharmacol; 1991 Jun; 43(6):430-2. PubMed ID: 1681057
[TBL] [Abstract][Full Text] [Related]
38. Polypseudorotaxanes of pegylated α-cyclodextrin/polyamidoamine dendrimer conjugate with cyclodextrins as a sustained release system for DNA.
Motoyama K; Hayashida K; Higashi T; Arima H
Bioorg Med Chem; 2012 Feb; 20(4):1425-33. PubMed ID: 22277591
[TBL] [Abstract][Full Text] [Related]
39. Modified beta-cyclodextrin (SBE7-beta-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits.
Jarho P; Järvinen K; Urtti A; Stella VJ; Järvinen T
J Pharm Pharmacol; 1996 Mar; 48(3):263-9. PubMed ID: 8737051
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine.
Mady FM; Abou-Taleb AE; Khaled KA; Yamasaki K; Iohara D; Taguchi K; Anraku M; Hirayama F; Uekama K; Otagiri M
Int J Pharm; 2010 Sep; 397(1-2):1-8. PubMed ID: 20600734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
